Research comparison
Tirzepatide vs. semaglutide
Semaglutide is a pure GLP-1 analogue, tirzepatide a dual agonist at GIP and GLP-1 receptors. Both carry a fatty-acid side chain that extends the half-life through albumin binding, and both are approved drug substances.
| Property | Tirzepatid | Semaglutid |
|---|---|---|
| Profile | Dual agonist at the GIP and GLP-1 receptors with a fatty-acid side chain; approved as a medicinal substance. | Lipidated GLP-1 analogue with a half-life of about one week; approved as a medicinal substance in several products. |
| Sequence | – | – |
| Length | – | – |
| Formula | C₂₂₅H₃₄₈N₄₈O₆₈ | C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molar mass | 4,813 g/mol | 4,114 g/mol |
| CAS | 2023788-19-2 | 910463-68-2 |
| Purity (current batch, HPLC) | – | – |
| Price per mg from | €5.40 | €4.50 |
In the range
For research and laboratory use only. Not for use in humans or animals. The data summarises literature and lab reports; it is not a recommendation for use.